This is why. Great announcement today. Looking forward to Float next year. Been a excellent investment so far.
Column 1
Column 2
0
Column 1
0
13 August 2020
Shareholder AnnouncementDear Shareholder,I am pleased to announce that we have entered into an Agreement with MSD (or Merck Sharp & Dohme, tradename of Merck & Co., USA), to evaluate our lead anticancer pharmaceutical tigilanol tiglate in combination with MSD’s Keytruda® (pembrolizumab) in patients with melanoma. The Agreement encompasses a clinical trial collaboration to investigate the safety and preliminary efficacy of tigilanol tiglate when administered in combination with Keytruda® in a Phase Ib/IIa open label, dose escalation study. What we hope to see through this program, is that when combined, tigilanol tiglate and Keytruda® will be safe and produce an additive anti-tumour immune response with an improved outcome for patients. This clinical collaboration is a significant milestone for QBiotics, and we are delighted to work with such a high calibre company as MSD on this study. Melanoma is the second human application QBiotics is pursuing for tigilanol tiglate following on from our Phase Ib/IIa clinical trial in patients with Head and Neck Squamous Cell Carcinoma which commenced in December 2019. This latest announcement is an important step forward as we look to continue to expand the human application of tigilanol tiglate in solid tumours. Thank you for your ongoing support, which underpins all of our work. Together we will continue to build an extraordinary company. If you have any questions, please do not hesitate to contact us. Shareholder enquires should be directed to QBiotics Group Shareholder Relationship Manager, Mr Ken Pointon. Mr Pointon can be contacted by telephoning (07) 3870 8933 or emailing [email protected] Yours sincerely,Dr Victoria GordonCEO & Managing DirectorQBiotics Group Limited [/table]
